Our long-term research interest is to improve the outcome for children with neuroblastoma. We are conducting laboratory-based research focused on understanding the cellular pathways that drive clinically aggressive neuroblastoma growth in order to identify actionable mutations that can be targeted and tested in clinical trials. We have an active collaboration with Drs. Chuan He and Lucy Godley investigating the epigenetic landscape of neuroblastoma. We are also collaborating with Dr. Sam Volchenboum and Dr. Robert Grossman to build an International Neuroblastoma Risk Group (INRG) Data Commons that contain phenotype data on a large cohort of neuroblastoma patients diagnosed around the world. The database was built with technology that allows connections with other databases that contain clinical and genomic information on patients with neuroblastoma diagnosed around the world. These data are available to investigators for data mining studies. Currently, clinical information on >20,000 patients with neuroblastoma are included in the INRG Data Commons. More than 20 research projects have been performed, and many of which would not have been possible with smaller patient cohorts.
Northwestern University
Chicago, Illinois
- Fellow in Pediatric Hematology/Oncology
1987
Michael Reese Hospital and Medical Center
Chicago, Illinois
- Resident in Pediatrics
1984
University of Illinois Medical School
Chicago, Illinois
MD
1980
Northwestern University
Evanston, Illinoins
BA - Biology
1976
T-cell inflammation is prognostic of survival in patients with high-risk neuroblastoma enriched for an adrenergic signature.
T-cell inflammation is prognostic of survival in patients with high-risk neuroblastoma enriched for an adrenergic signature. bioRxiv. 2023 Jun 28.
PMID: 37425883
Survival of Patients With Neuroblastoma After Assignment to Reduced Therapy Because of the 12- to 18-Month Change in Age Cutoff in Children's Oncology Group Risk Stratification.
Survival of Patients With Neuroblastoma After Assignment to Reduced Therapy Because of the 12- to 18-Month Change in Age Cutoff in Children's Oncology Group Risk Stratification. J Clin Oncol. 2023 06 10; 41(17):3149-3159.
PMID: 37098238
Multimodality treatment for recurrent neuroblastoma in the central nervous system.
Multimodality treatment for recurrent neuroblastoma in the central nervous system. Pediatr Blood Cancer. 2023 04; 70(4):e30227.
PMID: 36720647
Long-Term Morbidity and Mortality Among Survivors of Neuroblastoma Diagnosed During Infancy: A Report From the Childhood Cancer Survivor Study.
Long-Term Morbidity and Mortality Among Survivors of Neuroblastoma Diagnosed During Infancy: A Report From the Childhood Cancer Survivor Study. J Clin Oncol. 2023 03 10; 41(8):1565-1576.
PMID: 36525618
A Community Call to Action to Prioritize Inclusion and Enrollment of Women in HIV Cure-related Research.
A Community Call to Action to Prioritize Inclusion and Enrollment of Women in HIV Cure-related Research. J Acquir Immune Defic Syndr. 2022 12 15; 91(5):e12-e14.
PMID: 36083494
MYCN and HIF-1 directly regulate TET1 expression to control 5-hmC gains and enhance neuroblastoma cell migration in hypoxia.
MYCN and HIF-1 directly regulate TET1 expression to control 5-hmC gains and enhance neuroblastoma cell migration in hypoxia. Epigenetics. 2022 12; 17(13):2056-2074.
PMID: 35942521
Outcomes Following GD2-Directed Postconsolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children's Oncology Group.
Outcomes Following GD2-Directed Postconsolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children's Oncology Group. J Clin Oncol. 2022 Dec 10; 40(35):4107-4118.
PMID: 35839426
Efficacy of post-induction therapy for high-risk neuroblastoma patients with end-induction residual disease.
Efficacy of post-induction therapy for high-risk neuroblastoma patients with end-induction residual disease. Cancer. 2022 08 01; 128(15):2967-2977.
PMID: 35665495
Rethinking high-risk neuroblastoma treatment.
Rethinking high-risk neuroblastoma treatment. Pediatr Blood Cancer. 2022 08; 69(8):e29730.
PMID: 35441788
The Experience of Children With Neuroblastoma and Their Parents During Single-Room Isolation for 131I-Metaiodobenzylguanidine Therapy: A Qualitative Descriptive Study.
The Experience of Children With Neuroblastoma and Their Parents During Single-Room Isolation for 131I-Metaiodobenzylguanidine Therapy: A Qualitative Descriptive Study. J Pediatr Hematol Oncol Nurs. 2022 Sep-Oct; 39(5):304-316.
PMID: 36129889
AACR-Joseph H. Burchenal Memorial Award for Outstanding Achievement in Clinical Cancer Research
University of Chicago
2019
The Samuel Spector Award for Mentorship, Department of Pediatrics
University of Chicago
2018
American Society of Clinical Oncology Pediatric Oncology Award
2016
Fellow of the American Society of Clinical Oncology (FASCO)
2016
Senior Faculty Scholar in the Bucksbaum Institute for Clinical Excellence
University of Chicago
2014
Association for Women in Science (AWIS) Chicago Innovator Award
2012
Treasurer, American Society of Clinical Oncology
2012 - 2015
Pritzker Scholar
University of Chicago
2012